New Weight Loss Pill Delivers 12% Results in 36 Weeks

Millions of people struggling with weight management may soon have a game-changing option that doesn't require a single injection.

A new oral medication called aleniglipron helped adults with obesity lose up to 12.1% of their body weight over 36 weeks, according to a phase II clinical trial published in Nature Medicine. The study tracked 230 adults across 38 U.S. medical centers, with participants taking daily doses ranging from 45 to 120 milligrams.

The results speak volumes. People taking the highest dose lost an average of 12.1% of their body weight, while those on the middle dose lost 10.7%. Even the lowest dose group saw 9% weight reduction. Meanwhile, the placebo group lost just half a percent.

Dr. Robert Kushner, professor emeritus at Northwestern Medicine and study co-author, explains what makes this pill different from popular injectable drugs like Wegovy and Ozempic. "It's a small molecule, which means it's chemically made and could be taken with or without food," he said. "Because of that, you can potentially combine it with other medications."

That chemical difference matters more than it might sound. Current GLP-1 treatments are peptide-based medications that require refrigeration, regular injections, and complex manufacturing processes. These barriers have left countless patients unable to access treatments that could help them.

Aleniglipron works the same way as existing GLP-1 drugs by mimicking a natural hormone that reduces appetite and increases feelings of fullness. But as a small-molecule drug similar to aspirin or blood pressure medication, it could be produced at much larger scales to meet soaring demand.

The Bright Side

The safety profile looks promising too. Side effects were mostly mild stomach issues that decreased as the study continued. Only 10.4% of participants stopped treatment, and researchers found no liver damage or unexpected safety concerns.

The pill's potential extends beyond convenience. Easier manufacturing could mean lower costs and wider availability, helping address the massive gap between people who need obesity treatment and those who can access it. If a medication works similarly to an injection but can be made as simply as common pills, that's progress that ripples outward.

The research team is now preparing for phase III trials, where they'll slow down the dose increase even further to improve tolerability. "We found a dose that seems to be effective," Kushner noted, expressing optimism about the next testing phase.

For the estimated 42% of American adults living with obesity, this development represents more than scientific achievement. It's hope in pill form, potentially opening doors that needles and refrigerators kept closed.